

*Disclaimer :*

*The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.*

**M.7276 - GLAXOSMITHKLINE / NOVARTIS VACCINES BUSINESS (EXCL. INFLUENZA) / NOVARTIS CONSUMER HEALTH BUSINESS**

**SECTION 1.2**

**Description of the concentration**

1. On April 22, 2014, GlaxoSmithKline plc. (“GSK”) and Novartis A.G. (“Novartis”) announced a three-part inter-conditional transaction concerning their Vaccines, Consumer Health, and Oncology businesses.
  - As one component of the overall transaction, GSK will acquire sole control of Novartis’ human vaccines business (excluding Novartis’ influenza vaccines business) (the “Vaccines Transaction”).
  - As a second component of the overall transaction, the Parties will contribute their respective global non-prescription (or “over-the-counter”) pharmaceuticals businesses into a new venture to be named GSK Consumer Healthcare, of which GSK will acquire sole control (the “OTC Transaction”).
2. The Vaccines Transaction and the OTC Transaction qualify for review as a single concentration under the EU Merger Regulation and are notified together as Case COMP/M.7276.
3. As a third component of the overall transaction, Novartis has agreed to acquire GSK’s portfolio of oncology pharmaceuticals (together with certain opt-in rights to GSK’s current and future oncology R&D pipeline). This part of the overall transaction has been notified as a separate concentration, as Case COMP/M.7275.